HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
Pablo Mandó,1 Federico Waisberg,2 Rosario Pasquinelli,1 Sergio Rivero,2 Alexis Ostinelli,2 Florencia Perazzo1 1Clinical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina; 2Clinical Oncology Department, Ins...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2023-02-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/her2-directed-therapy-in-advanced-breast-cancer-benefits-and-risks-peer-reviewed-fulltext-article-OTT |
| _version_ | 1797903168443514880 |
|---|---|
| author | Mandó P Waisberg F Pasquinelli R Rivero S Ostinelli A Perazzo F |
| author_facet | Mandó P Waisberg F Pasquinelli R Rivero S Ostinelli A Perazzo F |
| author_sort | Mandó P |
| collection | DOAJ |
| description | Pablo Mandó,1 Federico Waisberg,2 Rosario Pasquinelli,1 Sergio Rivero,2 Alexis Ostinelli,2 Florencia Perazzo1 1Clinical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina; 2Clinical Oncology Department, Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, ArgentinaCorrespondence: Pablo Mandó, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Galvan 4102, Ciudad Autónoma de Buenos Aires, 1431, Argentina, Tel +54 11 61204997, Email pablomando@gmail.comAbstract: Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. This includes monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and, recently, antibody–drug conjugates (ADCs). With the advent of these new alternatives, the decision-making process has become more complex, especially with regard to the treatment sequence possibilities. In spite of the fact that overall survival has significantly improved accordingly, resistance to treatment remains a challenge in HER2-positive breast cancer. The introduction of new agents has created awareness regarding new potential specific adverse events, and consequently, their increasing application pose major challenges in daily patient care. This review describes the therapeutic landscape for HER2-positive advanced breast cancer (ABC) and evaluates its benefits and risks in the clinical setting.Keywords: breast cancer, HER2, monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugates |
| first_indexed | 2024-04-10T09:28:37Z |
| format | Article |
| id | doaj.art-4f57eaa35ea140078cb30ebd1d2f84c2 |
| institution | Directory Open Access Journal |
| issn | 1178-6930 |
| language | English |
| last_indexed | 2024-04-10T09:28:37Z |
| publishDate | 2023-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | OncoTargets and Therapy |
| spelling | doaj.art-4f57eaa35ea140078cb30ebd1d2f84c22023-02-19T13:56:56ZengDove Medical PressOncoTargets and Therapy1178-69302023-02-01Volume 1611513281753HER2-Directed Therapy in Advanced Breast Cancer: Benefits and RisksMandó PWaisberg FPasquinelli RRivero SOstinelli APerazzo FPablo Mandó,1 Federico Waisberg,2 Rosario Pasquinelli,1 Sergio Rivero,2 Alexis Ostinelli,2 Florencia Perazzo1 1Clinical Oncology Department, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Ciudad Autónoma de Buenos Aires, Argentina; 2Clinical Oncology Department, Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, ArgentinaCorrespondence: Pablo Mandó, Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), Galvan 4102, Ciudad Autónoma de Buenos Aires, 1431, Argentina, Tel +54 11 61204997, Email pablomando@gmail.comAbstract: Around 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2). In this setting, anti-HER2-targeted agents are the cornerstone of cancer therapeutic strategies. This includes monoclonal antibodies, tyrosine kinase inhibitors (TKIs) and, recently, antibody–drug conjugates (ADCs). With the advent of these new alternatives, the decision-making process has become more complex, especially with regard to the treatment sequence possibilities. In spite of the fact that overall survival has significantly improved accordingly, resistance to treatment remains a challenge in HER2-positive breast cancer. The introduction of new agents has created awareness regarding new potential specific adverse events, and consequently, their increasing application pose major challenges in daily patient care. This review describes the therapeutic landscape for HER2-positive advanced breast cancer (ABC) and evaluates its benefits and risks in the clinical setting.Keywords: breast cancer, HER2, monoclonal antibodies, tyrosine kinase inhibitors, antibody–drug conjugateshttps://www.dovepress.com/her2-directed-therapy-in-advanced-breast-cancer-benefits-and-risks-peer-reviewed-fulltext-article-OTTbreast cancer – her2 – monoclonal antibodies – tyrosine kinase inhibitors – antibody drug conjugates |
| spellingShingle | Mandó P Waisberg F Pasquinelli R Rivero S Ostinelli A Perazzo F HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks OncoTargets and Therapy breast cancer – her2 – monoclonal antibodies – tyrosine kinase inhibitors – antibody drug conjugates |
| title | HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks |
| title_full | HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks |
| title_fullStr | HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks |
| title_full_unstemmed | HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks |
| title_short | HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks |
| title_sort | her2 directed therapy in advanced breast cancer benefits and risks |
| topic | breast cancer – her2 – monoclonal antibodies – tyrosine kinase inhibitors – antibody drug conjugates |
| url | https://www.dovepress.com/her2-directed-therapy-in-advanced-breast-cancer-benefits-and-risks-peer-reviewed-fulltext-article-OTT |
| work_keys_str_mv | AT mandop her2directedtherapyinadvancedbreastcancerbenefitsandrisks AT waisbergf her2directedtherapyinadvancedbreastcancerbenefitsandrisks AT pasquinellir her2directedtherapyinadvancedbreastcancerbenefitsandrisks AT riveros her2directedtherapyinadvancedbreastcancerbenefitsandrisks AT ostinellia her2directedtherapyinadvancedbreastcancerbenefitsandrisks AT perazzof her2directedtherapyinadvancedbreastcancerbenefitsandrisks |